These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 30992164)

  • 21. Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.
    Li Z; Chen Y; Zhou Z; Deng L; Xu Y; Hu L; Liu B; Zhang L
    Eur J Med Chem; 2019 Feb; 164():352-365. PubMed ID: 30605833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.
    Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H
    Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases.
    Christiansen E; Watterson KR; Stocker CJ; Sokol E; Jenkins L; Simon K; Grundmann M; Petersen RK; Wargent ET; Hudson BD; Kostenis E; Ejsing CS; Cawthorne MA; Milligan G; Ulven T
    Br J Nutr; 2015 Jun; 113(11):1677-88. PubMed ID: 25916176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
    Negoro N; Sasaki S; Mikami S; Ito M; Suzuki M; Tsujihata Y; Ito R; Harada A; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Kogame A; Matsunaga S; Yasuma T; Momose Y
    ACS Med Chem Lett; 2010 Sep; 1(6):290-4. PubMed ID: 24900210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
    Christiansen E; Urban C; Grundmann M; Due-Hansen ME; Hagesaether E; Schmidt J; Pardo L; Ullrich S; Kostenis E; Kassack M; Ulven T
    J Med Chem; 2011 Oct; 54(19):6691-703. PubMed ID: 21854074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold.
    Krasavin M; Lukin A; Zhurilo N; Kovalenko A; Zahanich I; Zozulya S; Moore D; Tikhonova IG
    Bioorg Med Chem; 2016 Jul; 24(13):2954-2963. PubMed ID: 27229618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
    Christiansen E; Due-Hansen ME; Urban C; Merten N; Pfleiderer M; Karlsen KK; Rasmussen SS; Steensgaard M; Hamacher A; Schmidt J; Drewke C; Petersen RK; Kristiansen K; Ullrich S; Kostenis E; Kassack MU; Ulven T
    ACS Med Chem Lett; 2010 Oct; 1(7):345-9. PubMed ID: 24900217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes.
    Wang B; Cai Z; Yao H; Jiao S; Chen S; Yang Z; Huang W; Ren Q; Cao Z; Chen Y; Zhang L; Li Z
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114883. PubMed ID: 36343410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.
    Guo B; Guo S; Huang J; Li J; Li J; Chen Q; Zhou X; Xie X; Yang Y
    Bioorg Med Chem; 2018 Dec; 26(22):5780-5791. PubMed ID: 30392954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes.
    Christiansen E; Hansen SV; Urban C; Hudson BD; Wargent ET; Grundmann M; Jenkins L; Zaibi M; Stocker CJ; Ullrich S; Kostenis E; Kassack MU; Milligan G; Cawthorne MA; Ulven T
    ACS Med Chem Lett; 2013 May; 4(5):441-445. PubMed ID: 23687558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role and Future of FFA1 as a Therapeutic Target.
    Ghislain J; Poitout V
    Handb Exp Pharmacol; 2017; 236():159-180. PubMed ID: 27807697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.
    Negoro N; Sasaki S; Mikami S; Ito M; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Morohashi A; Nonaka M; Matsunaga S; Yasuma T; Momose Y
    J Med Chem; 2012 Apr; 55(8):3960-74. PubMed ID: 22490067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR40) agonists.
    Krasavin M; Lukin A; Bakholdina A; Zhurilo N; Onopchenko O; Borysko P; Zozulya S; Moore D; Tikhonova IG
    Eur J Med Chem; 2017 Nov; 140():229-238. PubMed ID: 28938138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
    Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schmidt J; Hansen SV; Hudson BD; Zaibi M; Markussen SB; Hagesaether E; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
    J Med Chem; 2013 Feb; 56(3):982-92. PubMed ID: 23294321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK-875).
    Lukin A; Bakholdina A; Zhurilo N; Onopchenko O; Zhuravel E; Zozulya S; Gureev M; Safrygin A; Krasavin M
    Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000275. PubMed ID: 33270252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold.
    Li Z; Chen Y; Zhang Y; Jiang H; Liu Y; Chen Y; Zhang L; Qian H
    Bioorg Chem; 2018 Oct; 80():296-302. PubMed ID: 29980115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer.
    Christiansen E; Hudson BD; Hansen AH; Milligan G; Ulven T
    J Med Chem; 2016 May; 59(10):4849-58. PubMed ID: 27074625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Wang X; Xu X; Yang J; Qiu Q; Qiang H; Huang W; Qian H
    Bioorg Med Chem; 2015 Oct; 23(20):6666-72. PubMed ID: 26420383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
    Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK
    Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.